Presentation

Orexo commercialises and develops pharmaceuticals and digital therapies to address unmet needs within mental illness and substance use disorders. The main market is the US market where Orexo commercialises its lead product ZUBSOLV® for the treatment of opioid use disorder. Orexo also has three digital therapeutics developed together with GAIA AG and launched in the US. Finally, Orexo has a proprietary drug delivery platform amorphOX® with several ongoing clinical development projects based on the technology.

Recent highlights
In Q2, net revenues amounted to 147.8M SEK (+3.5%), with lead product ZUBSOLV®’s net sales grew 11% YoY due to positive payer mix and stronger USD vs SEK.
In February, Orexo announced that its lead product ZUBSOLV® was added to NY State Medicaid MAT Preferred Drug List, thus available to patients with Medicaid insurance in NY State as a preferred product. In July, Orexo announced initiation of its first explorative human clinical study for OX640, an adrenaline rescue medication with nasal delivery based on the proprietary drug delivery platform amorphOX®

Outlook
Financial outlook 2022 includes the following: (1) Due to the continuing pandemic the buprenorphine/naloxone market will show a growth pace in line with 2021, and reach a level of 5-8%, (2) In H2 ZUBSOLV® net sales in USD will increase comparing to H1, (3) OPEX will decline from 2021 to 650-700 MSEK with the current business plans and activity level in legal processes, and (4) US Pharma EBIT will exceed 50 percent on a full year basis.